Zemplar Injection, a vitamin D analog, is indicated for secondary hyperparathyroidism due to chronic renal failure. The biological effects of paricalcitol are mediated through binding of the vitamin D receptor, which results in the selective activation of the vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting parathyroid hormone synthesis and secretion.